

Eirini Papapetrou Candidate Statement

“Why would you be a good candidate for the role you are nominated for and how do you think you would be able to positively impact the society if elected?”

Why I might be a good candidate for a leadership position in ISEH:

I combine scientific status with leadership experience, strategic thinking, a vision for where the field is headed in the future and strong commitment to advancing the society’s mission and the field of hematology.

Motivation: I am honored to be considered for the ISEH Board of Directors. ISEH has played an important role in advancing my career and the career of several of my trainees. I welcome the opportunity to serve in this role and contribute to the society’s mission. My current career stage allows me to commit the time and effort required for this position. As a tenured professor with leadership experience but without heavy administrative load and with a mature lab and research program I have the flexibility to take on this role.

Scientific leadership: I have a broad research background in basic, translational and clinical hematology, spanning classical and malignant hematology. I trained in clinical hematology as a physician/scientist, in beta-globin gene and cell therapy, in pluripotent stem cell research and in leukemia biology. I am comfortable and effective in interacting with researchers across the entire spectrum from fundamental discovery scientists to clinical hematologists and across academia and industry. I have led a productive and well-funded laboratory for 13 years and trained several investigators who are now pursuing careers in academia and industry. I have a strong record of scientific contributions, including pioneering the modeling of human blood diseases with induced pluripotent stem cells.

Leadership roles: I am the founding director of the Center for the Advancement of Blood Cancer Therapies at Mount Sinai – a center that was born out of my vision to bring together basic, translational and clinical research in hematology and create joint resources for the hematology community within my institute and beyond. I have spearheaded initiatives under the auspices of professional societies – ISEH, ASH and ASGCT – including organizing symposia and workshops. Since 2022 I have co-organized in conjunction with ISEH the “hPSC-hematopoiesis” symposium – widely recognized as the premier forum for the hPSC-hematopoiesis community. I have served in various NIH study sections; as Chair of scientific committees of ASH and ASGCT, and as Associate editor and editorial board member for Molecular Therapy and Blood journals, respectively.